RAP 0.00% 20.5¢ resapp health limited

Ann: Positive Results for Australian Prospective Paediatric Study, page-256

  1. 26,804 Posts.
    lightbulb Created with Sketch. 1737
    A year from now, if they get it commercialise for paediatric, it will easily be a $1B+ MC.
    Then add the adults and sleep apnea and other products with partnerships from Lockheed Martin, etc.......$5B+, it's a huge health industry their product is entering and there are no known competitors with it's patents of the machine self learning algorithm IP which (if all goes well) have been approved by the FDA!!!
 
watchlist Created with Sketch. Add RAP (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.